Get Ownership of your IP Right; Otherwise it can Turn into a Nightmare!

Oct 1, 2014

When filing a patent application, there are lots of things to consider. Most of the attention is directed towards getting the disclosure of the invention right and ensuring that you have adequately covered your commercial product/concept to prevent your competitors from entering the market space. Jenny Donald of Forresters warns that too often, little thought is given to who actually owns the invention. And if you get this wrong, it can be incredibly difficult to rectify the situation at a later stage. ...

Read More

Global Tracking Regulations Present Challenges and Benefits

Oct 1, 2014

Lars Hoejberg of NNIT looks into serialisation, the foundation of any tracking system. Drug makers are facing an ever-increasing challenge as more countries implement serialisation and tracking regulations and set compliance deadlines, in an effort to ensure the safety and quality of prescription drugs being sold within their borders. Complying with regulations coming into effect will be a demanding task due to a lack of global harmonisation. ...

Read More

Funding Options for R&D in the Life Sciences Sector

Oct 1, 2014

Typically, funding for R&D and business growth has been hard to secure over previous years due to the financial crisis. However, now that the financial uncertainty is passing, there is a definite sense of increased confidence in the economy with funding options returning and becoming more readily available and accessible to life sciences businesses. Nigel Greenaway and Laura Herdman of Greenaway Scott discuss the various funding options available and the positive impacts and initiatives these bring to businesses in the life sciences industry. ...

Read More

The 3E Principle: Key Considerations for Selecting and Outsourcing to a Vendor

Oct 1, 2014

Influenced by forces such as macroeconomics, politics, regulations, population growth and aging, there has been a major shift in the way biopharmaceutical companies conduct business. There is ever-increasing pressure to comply with evolving regulations along with cost reductions in order to grow business. Dr Chitra Lele of Sciformix Corporation outlines the “3E Principle” of Effectiveness, Efficiency and Economics; key parameters organisations should consider when selecting an outsourcing partner to assist with knowledge-based activities in drug development and post-marketing stages of the product lifecycle. ...

Read More

The Interim Exec Community calls for a ‘Conscious Coupling’ of RPOs and Interims Specialists

Oct 1, 2014

Pharmaceutical companies have widely adopted strategies to outsource elements of their business operations, as part of an ongoing drive to deliver a more flexible model that unlocks cost efficiencies and alleviates some aspects of risk associated with drug development. As Dafydd Wright, Director of Interims of RSA, explains, recruiting talent is one such element. However, pharmaceutical companies should be wary of saving on recruitment at the risk of missing out on the best candidates, particularly when it comes to senior staff. ...

Read More